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dose' was defined as a mean gland dose of above 50 Gy. The four 
groups were: high thyroid and pituitary doses (HTHP group); high 
thyroid and low pituitary doses (HTLP group); low thyroid and high 
pituitary doses (LTHP group) and low thyroid and pituitary doses (LTLP 
group). Repeated measurements of the fT3, fT4 and TSH were taken 
at 3, 6, 12 and 18 months after completion of radiotherapy. Any 
abnormal thyroid hormone levels and incidences of hypothyroidism 
were identified and analysed with respect to the four different 
patient groups defined above.  
Results: In general, the thyroid gland received relatively higher dose 
than the pituitary gland, with the average mean and D50 thyroid dose 
about 60% higher than that of the pituitary. 22 patients (33.8%) and 17 
patients (26.2%) received high mean thyroid and pituitary doses of 
over 50 Gy respectively. At the 18 months post-RT, 4 patients (6.2%) 
developed overt hypothyroidism, 9 (13.8%) developed subclinical 
hypothyroidism and 2 (3.1%) developed central hypothyroidism (Table 
1). The incidence of abnormal thyroid function was highest in the 
HTHP group, in which 5 out of 6 cases (83.3%) developed 
hypothyroidism followed by the HTLP group with an incidence of 50%. 
The LTHP and LTLP groups showed much lower incidence of 
hypothyroidism (<10%). 
 
  
Conclusions: Patients who received both high thyroid and pituitary 
glands doses carried the highest risks of abnormal thyroid functions. 
High thyroid dose was a more influential factor than high pituitary 
dose in inducing post-RT hypothyroidism. Therefore, measure to keep 
the mean thyroid dose below 50 Gy in treatment planning was 
essential to minimize the thyroid complications. 
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Purpose/Objective: External radiation therapy (ERT) and 
chemotherapy are currently used for the treatment of head and neck 
cancer. These therapies are often associated with mucositis and 
xerostomia while hyperpigmentation of the tongue is a rare event. 
The aim of our study was to study all cases of dark tongue in patients 
(pts) treated with ERT on the head and neck area by performing a 
routine microbiological test and looking for possible correlations with 
ERT or other therapies administered. 
Materials and Methods: In a period of 9 months we observed 10 cases 
of hyperpigmentation of tongue. Four pts underwent radical surgery 
before ERT, 2 pts had conservative surgery. Six pts were treated 
concurrent with chemotherapy. Eight patients were treated with 
3DCRT, 2 pts with IMRT. The evaluation of acute toxicity was made 
using the RTOG criteria. Lingual swabs were performed at the 
appearance of lingual discoloration. An assessment of the dose-volume 
histogram (DVH) was carried out for each patient. 
  
Results: Pts developed hyperpigmentation of tongue at a mean dose 
of 40,65 Gy (range 22 – 68 Gy). For all pts, the brown coloration was 
on the anterior half of dorsal surface of mobile tongue without pain, 
burning sensation or other type of tongue distress. Mucositides G2 
were observed in 5 pts and G1 in 1 pt. Salivary gland toxicity G2 was 
detected in 5 pts and G1 in 1 pt. No pts developed hematologic 
toxicity. In only one case (5%) an infection by two microorganisms 
(Klebsiella pneumoniae and Candida spp.) was reported, while in all 
other cases there were monomicrobic infections represented in 50% of 
the cases by Candida spp, in the 45% by gram-negative bacterial 
pathogens (Acinetobacter lwoffii, Acinetobacter Baumannii, 
Enterobacter cloacae, Pseudomonas spp.).  From an initial 
assessment, evaluating the DVH data, we did not observe a direct 
correlation between the appearance of hyperpigmentation of tongue 
and the dose absorbed by the tongue nor by parotid glands. We did 
not find a correlation between the initial infection and the 
administration of chemotherapy. All patients assumed topical therapy 
for the prevention and palliative treatment of xerostomia and 
mucositis. In order to treat hyperpigmentation of the dorsal surface of 
tongue, five patients (2 with Candida and 3 with bacterial infection) 
did not assume any therapy while the others were treated with 
systemic antifungal therapy or with antibiotic depending by the 
microbial agent reported. It may be stated that administration of 
systemic targeted therapy did not give any advantage as to the time 
of resolution of the black tongue. 
Conclusions: We believe that for all patients, the hyperpigmentation 
of tongue is related to the changed microenvironmental conditions of 
the oral cavity favoring the development of opportunistic 
microorganisms. We would also like to emphasize the need for a 
microbiological swab test before prescribing any drug to subjects with 
a black tongue discoloration.  
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Purpose/Objective: Radiotherapy alone (RT) or in combination with 
chemotherapy (CRT) is a standard of care for patients in locally 
advanced squamous cell carcinoma head and neck cancer (LA-HNSCC). 
However, RT is associated with side effects, which can have a 
significant impact on the QoL. The purpose of this study was to 
investigate the longitudinal changes in QoL for patients with LA-
HNSCC following RT or CRT. 
Materials and Methods: From September 2008 to February 2010, 205 
patients with LA-HNSCC were included. The data pertaining to their 
QoL were collected using the European Organization for Research and 
Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-
C30) and the EORTC Head and Neck Module(QLQ-H&N35) before RT 
and 12 months after the end of RT. The data of all items and scales of 
the EORTC QLQ-C30 and the EORTC QLQ-H&N35 were transformed to a 
0–100 scale for presentation according to the guidelines of the EORTC. 
For statistical evaluation the student t-test was performed with 
significance level of p< 0.05. 
Results: In general, during the 1 year follow-up after the end of RT 
the QoL of patients increased and the global QoL was not statistically 
different than prior RT. The most significant improvement was 
observed for the following issues: appetite, pain, nausea and 
vomiting, and fatigue. However, after 1 year from the end of RT the 
QoL for many subscales is still lower than prior treatment. For 
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subscales such as dry mouth, stick saliva, taste impairment, and tooth 
pain the differences were found, which were both statistical (p < 
0.05) and clinically (difference >10 points) significant when compared 
with prior RT.  
Conclusions: The study showed that the most treatment-related QoL 
issues, which were deteriorated during treatment, improved in the 
first year after RT, but still dry mouth, stick saliva, taste impairment, 
and tooth pain are more pronounced than prior RT. However, these 
issues did not influence on significant difference between global QoL 
prior and 1 year after RT. 
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Purpose/Objective: To ascertain the reasons for recurrences in 
Radiation Therapy (RT), ChemoRadiation Therapy (CRT) and Surgical 
Treatment (ST) of early stages glottic laryngeal cancer. 
Materials and Methods: A retrospective analysis of 136 patients with 
SCC of the larynx T1-2 from 1992 to 2007. T1 - 67 patients, T2 - 69 
patients, including T1-2N+ 4 (2.9%) patients. 91 patients with glottic 
cancer received RT, CRT, and ST. Overall 5-year survival rate and 
median survival time: 84,4% and 82 months (Kaplan Meier Survival 
curve). Recurrences were observed in 14 (15.4%) patients, of which 
only 3 (21.4%) died from progression. 
Results: In RT and CRT - 50 patients, tumor recurrence was observed 
in 6 (12%) patients. With the defeat of the anterior commissure tumor 
(ACT) recurrence was observed in 4 (16.7%) patients, without anterior 
commissure tumor (WACT) - in 2 (7.7%) patients. The risk of 
recurrence increases by 2 times in ACT. It should be noted that 5 of 
the 6 recurrences detected after chemoradiation therapy, and 1 
patient in combination with distant metastases. After RT - only 1 
recurrence. Overall 5-year survival rate and median survival: CRT - 
87.5% and 59 months, RT - 75% and 111 months (p), respectively. Only 
2 patients died from progression. In the ST group (41 patients) - 8 
(19.5%) patients with recurrences. In 17 patients with ACT- 6 (35.3%) 
relapsed. In 24 patients WACT - 2 (8.3%) relapsed. Thus the risk of 
recurrence after surgical treatment is 4.2 times higher in patients 
with ACT and in 2 times higher compared with RT. It should be noted, 
that in 9 WACT patients received laser destruction (LD) recurrence 
detected in only 1 patient (11%). Cordectomy (CE) and partial vertical 
laryngeal resections (PVLR) performed 32 patients - relapses were 
observed in 7 (21.8%), of which CE – in 2 (12.5%) of 16 patients, PVLR - 
in 5 (31.3%) of 16. Of the these 7 patients: 2 (28.6%) with well 
differentiated tumor (WDT) and 5 (71.4%) with moderate 
differentiated tumor; surgical resections with negative margins found 
only in 1 patient. Overall 5-year survival rate and median survival - 
90.3% and 91 months. Only 1 patient died from progression. 
Conclusions: The basic reason for relapse - the incorrect treatment 
strategy. 1) The most effective treatment - radically RT, regardless of 
the degree of tumor differentiation and mode of fractionation. ACT 
increases the risk of recurrence in 2 times. 2) LD in WACT patients 
(T1a) – the same good method as RT. 3) Partial laryngeal resections 
(CE, PVLR) in WDT the same good methods as RT. ACT defeat risk of 
recurrence is 2 times higher than after RT. Perhaps a more wide 
excision of the tumor will improve the results of organ-saving 
operations. Surgical resections with pathologic margins negative for 
tumor requires additional treatment. ST needs further investigation 
and correction. 4) CRT is not inferior to other treatments in respect of 
remission of the disease, but the median survival with CRT is 2 times 
lower than with RT (p = 0.001) and 1.5 times lower than in the ST (p = 
0.01) , eliminating chemotherapy treatments for cancer of the larynx 
in the early stages. 
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Purpose/Objective: Anaplastic thyroid carcinomas (ATC) are among 
the most aggressive human malignancies. Only 1-2% of thyroid 
carcinomas are anaplastic, but the disease contributes to ≈ 50% of the 
mortality of thyroid cancers and median survival is ≤ 10 months. Our 
aim is to update recommendations for RT in the context of new 
irradiation techniques. 
Materials and Methods: A search of the French and English literature 
was performed with terms: thyroid carcinoma, anaplastic, 
chemoradiation, radiation therapy, surgery. Level-based evidence 
remains limited in the absence of prospective studies and the small 
size of retrospective series of this rare tumor. 
Results: Surgery when possible should be as complete as possible but 
without mutilation given the poor prognostic of ATC. It often consists 
of debulking resection only. It should be followed by systematic 
chemoradiation in ATC. Initiation of treatment is an emergency given 
the fast tumor doubling time of these tumors. The most promising 
results of chemoradiation to date have been shown in series of 
radiation therapy (± acceleration) combined with doxorubicin ± 
taxanes or cisplatin. Adjuvant chemotherapy (doxorubicin, cisplatine 
and/or taxane-based), given the metastatic potential of ATC, 
warrants further investigations. Data on neoadjuvant chemotherapy 
are missing. Intensity modulated radiation therapy offers clear 
dosimetric advantages and has the potential to improve tumor and 
nodal (posterior neck, mediastinum) coverage, i.e. locoregional 
control while optimally sparing the spinal cord, larynx, parotids, 
trachea and esophagus. PET-CT and MRI may be used for RT planning. 
Conclusions: Chemoradiation with debulking surgery whenever 
possible is the main stay of treatment of ATC. EBRT using IMRT has the 
potential to improve local control. Taxane-doxorubicin concomitant 
chemoradiotherapy is worth further investigations. 
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Purpose/Objective: Adenoid cystic carcinoma is a rare malignant 
neoplasma that accounts for less than 5% of head and neck cancers. 
Surgery is considered the mainstay treatment to the disease, 
however, clear surgical margins are difficult to achieve. Radiotherapy 
(RT) may improve locoregional control. The purpose of this study is to 
evaluate the effectiveness of RT for patients with head and neck 
adenoid cystic carcinoma with an attempt to identify significant 
prognostic factors. 
 Materials and Methods: A retrospective review of 25 patients who 
received RT in our department between January 2003 and May 2011 
was performed. Median age was 56 (28-79); 13 patients was female, 
12 patients was male. The subsite distribution was paranasal sinuses 
40% (n=10), oral cavity 24%(n=6), submandibular 20% (n= 5), parotid 
gland 16% (n=4). T and N stage distributions were T1:0%, T2:24%, 
T3:28%, T4:48% and N0:80%, N1:8%, N2:12%. None of the patients had 
distant metastasis at the time of diagnosis. Overall TNM stage 2, 3, 4 
distributions were 24%, 24%, 52%, respectively. Two patients had base 
of skull involvement. Ten (40%) patients had grade 3 tumor. Sixteen 
patients (64%) had microscopic perineural invasion; and 10 (40%) 
patients had positive surgical margin. Twenty-two (88%) patients had 
surgery and all patients received RT (22:postoperative, 
1:preoperative, 2:radiation alone). Conventional RT applied to 13 
patients, conformal RT applied to 12 patients. Median RT dose was 64 
Gy (40-70) with 2 Gy daily dose fraction. Six patients received 
cisplatin based chemotherapy concomitant to RT.  
Results: After median follow-up time of 46 (8.37-102) months, 18 
(72%) patients were alive (n=15 without disease, n=3 with disease) and 
7 (28%) patients were exitus. Five patients had distant, 1 patient had 
local and distant, 1 patient had local failure. Most common distant 
metastasis site was lung. Median overall survival time was 80.7 (51.75-
110) months. On univariate analysis patients with tumor stage (T4 vs 
T2+3; p=0.005) and overall stage (TNM stage 4 vs 2+3; p=0.009) 
showed worse overall survival. Close or positive surgical margin 
